FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2322151805> ?p ?o ?g. }

• W2322151805 abstract "Objective: We hypothesized that targeting ETrA could mitigate the deleterious effects of TBI. Background Traumatic brain injury results in multiple pathologies, including significant reduction in cerebral blood flow. Our laboratory have shown that endothelin-1 plays a major role in the induction of hypoperfusion. Furthermore, we demonstrated that the endothelin receptor A (ETrA) is upregulated as early as 4 hours post TBI and maintains upregulation up to 48 hours, thus temporally corresponding with the state of hypoperfusion. Design/Methods: Using a rodent model of diffuse traumatic brain injury (acceleration impact in Sprague-Dawley rats), we tested the effects of IV administration of a selective ETrA antagonist, Clazosentan administered at various times post TBI on CBF (as measured up to 48 hours post injury using arterial spin labeling MRI, n=6 per group) and behavioral outcome (measured up to 20 days post injury using a radial arm maze-spatial learning task, n=12-15 per group) following injury. Results: Our results indicate that when Clazosentan is administered at 30 minutes, 2 hours, or 4 hours after TBI there is a marked decrease in the extent of TBI-induced hypoperfusion. However, administration at 12 hours post-TBI resulted in variable effects (i.e., some animals improved, some worsened, and some remained the same). The most effective paradigm was a dual-administration approach in which drug was given at 2 and 24 hours post-TBI. Behavioral results recapitulated the blood flow results, showing that there was a trend towards improved behavioral outcome when Clazosentan was administered at 2 hours, however a significant improvement was seen when given at 2 and 24 hours. Conclusions: These results suggest that selective ETrA antagonism may be effective in mitigating the deleterious effects of TBI. Furthermore, it appears that our results help to define the “window of opportunity of drug delivery”. Supported by: NIH-NS064976(CK,PI), VARR&D-RX000224(CK, PI), and American Academy of Neurology(MK). Disclosure: Dr. Kaufman has nothing to disclose. Dr. Tiesma has nothing to disclose. Dr. Kreipke has received research support from Veterans Administration and National Institute of Health." @default.
• W2322151805 created "2016-06-24" @default.
• W2322151805 creator A5010860662 @default.
• W2322151805 creator A5087072415 @default.
• W2322151805 creator A5087230605 @default.
• W2322151805 date "2012-04-22" @default.
• W2322151805 modified "2023-09-25" @default.
• W2322151805 title "Novel Treatment for Traumatic Brain Injury (S47.004)" @default.
• W2322151805 doi "https://doi.org/10.1212/wnl.78.1_meetingabstracts.s47.004" @default.
• W2322151805 hasPublicationYear "2012" @default.
• W2322151805 type Work @default.
• W2322151805 sameAs 2322151805 @default.
• W2322151805 citedByCount "0" @default.
• W2322151805 crossrefType "journal-article" @default.
• W2322151805 hasAuthorship W2322151805A5010860662 @default.
• W2322151805 hasAuthorship W2322151805A5087072415 @default.
• W2322151805 hasAuthorship W2322151805A5087230605 @default.
• W2322151805 hasConcept C118552586 @default.
• W2322151805 hasConcept C126322002 @default.
• W2322151805 hasConcept C144980905 @default.
• W2322151805 hasConcept C146957229 @default.
• W2322151805 hasConcept C154281038 @default.
• W2322151805 hasConcept C157767197 @default.
• W2322151805 hasConcept C170493617 @default.
• W2322151805 hasConcept C2776345702 @default.
• W2322151805 hasConcept C2776885963 @default.
• W2322151805 hasConcept C2781017439 @default.
• W2322151805 hasConcept C42219234 @default.
• W2322151805 hasConcept C71924100 @default.
• W2322151805 hasConceptScore W2322151805C118552586 @default.
• W2322151805 hasConceptScore W2322151805C126322002 @default.
• W2322151805 hasConceptScore W2322151805C144980905 @default.
• W2322151805 hasConceptScore W2322151805C146957229 @default.
• W2322151805 hasConceptScore W2322151805C154281038 @default.
• W2322151805 hasConceptScore W2322151805C157767197 @default.
• W2322151805 hasConceptScore W2322151805C170493617 @default.
• W2322151805 hasConceptScore W2322151805C2776345702 @default.
• W2322151805 hasConceptScore W2322151805C2776885963 @default.
• W2322151805 hasConceptScore W2322151805C2781017439 @default.
• W2322151805 hasConceptScore W2322151805C42219234 @default.
• W2322151805 hasConceptScore W2322151805C71924100 @default.
• W2322151805 hasLocation W23221518051 @default.
• W2322151805 hasOpenAccess W2322151805 @default.
• W2322151805 hasPrimaryLocation W23221518051 @default.
• W2322151805 hasRelatedWork W1965274612 @default.
• W2322151805 hasRelatedWork W1990497167 @default.
• W2322151805 hasRelatedWork W2020764769 @default.
• W2322151805 hasRelatedWork W2028976687 @default.
• W2322151805 hasRelatedWork W2032440781 @default.
• W2322151805 hasRelatedWork W2032763129 @default.
• W2322151805 hasRelatedWork W2034449715 @default.
• W2322151805 hasRelatedWork W2041436408 @default.
• W2322151805 hasRelatedWork W2165467410 @default.
• W2322151805 hasRelatedWork W2796878188 @default.
• W2322151805 hasRelatedWork W2807364181 @default.
• W2322151805 hasRelatedWork W2885048584 @default.
• W2322151805 hasRelatedWork W2905068356 @default.
• W2322151805 hasRelatedWork W2972871198 @default.
• W2322151805 hasRelatedWork W3088571830 @default.
• W2322151805 hasRelatedWork W3092917558 @default.
• W2322151805 hasRelatedWork W3143097987 @default.
• W2322151805 hasRelatedWork W3154939124 @default.
• W2322151805 hasRelatedWork W3161474040 @default.
• W2322151805 hasRelatedWork W3213019191 @default.
• W2322151805 isParatext "false" @default.
• W2322151805 isRetracted "false" @default.
• W2322151805 magId "2322151805" @default.
• W2322151805 workType "article" @default.